arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

10x Genomics, Inc.

TXG
$57.97 ▼ -9.52 (-14.11%) at close
Industrials ·Laboratory Analytical Instruments ·USLaboratory Analytical Instruments
36 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
33
Health
Poor
Bearish
auto_awesome

Analytical Summary

10x Genomics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $7.5B
Dividend Yield —
Revenue Growth -12.6% ↘
Op. Margin -12.9% ↘
ROIC -2.3% ↘
FCF / Share $0.12 ↘
Trailing P/E —
Price / Book 9.1x
FCF Yield 0.2%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

36-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$151.04M
↓ -12.6% —
Net Income Profit after all expenses
$-13.47M
↑ +60.8% —
Operating Margin Operating profit as % of sales
-12.9%
↓ -14.6% 16th
FCF / Share Free cash flow per share
$0.12
↓ -38.1% —
Long-Term Debt Long-term obligations
$0.00
↓ -100.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
39
Returns ↑
38
Cash Quality
5

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 10 years · 36 quarters